NCT00881569

Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017

Extended Use of CS 7017 Upon Completion of Participation in a Clinical Study of CS-7017 in Subjects With Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Daiichi Sankyo · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This is a study of CS-7017 designed to allow participants who completed participation in a clinical study of CS-7017 without experiencing disease progression or unacceptable toxicity to continue treatment with study drug. Participants who have not progressed while receiving CS-7017 will continue to benefit from longer administration of the agent.

Detailed description

This is an open-label non-randomized study of CS-7017 designed to allow participants who completed participation in a clinical study of CS-7017 without experiencing disease progression or unacceptable toxicity to continue treatment with study drug.

Conditions

• Advanced Cancer

Interventions

Type	Name	Description
DRUG	CS-7017	CS-7017 administered orally, twice daily continuously for 6 weeks

Timeline

• Start date: 2009-03-01
• Primary completion: 2011-03-01
• Completion: 2011-09-01
• First posted: 2009-04-15
• Last updated: 2020-09-28
• Results posted: 2020-08-14

Locations

1 site across 1 country: United States